117 related articles for article (PubMed ID: 38703793)
1. Nasal application of kisspeptin-54 mitigates motor deficits by reducing nigrostriatal dopamine loss in hemiparkinsonian rats.
Sinen O; Sinen AG; Derin N; Aslan MA
Behav Brain Res; 2024 Jun; 468():115035. PubMed ID: 38703793
[TBL] [Abstract][Full Text] [Related]
2. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
3. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
Liu H; Jia L; Chen X; Shi L; Xie J
Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
[TBL] [Abstract][Full Text] [Related]
4. ser31 Tyrosine hydroxylase phosphorylation parallels differences in dopamine recovery in nigrostriatal pathway following 6-OHDA lesion.
Salvatore MF
J Neurochem; 2014 May; 129(3):548-58. PubMed ID: 24410633
[TBL] [Abstract][Full Text] [Related]
5. Altered melatonin MT
Kang NH; Carriere CH; Bahna SG; Niles LP
Brain Res; 2016 Dec; 1652():89-96. PubMed ID: 27693415
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Sleeman IJ; Boshoff EL; Duty S
Neuropharmacology; 2012 Dec; 63(7):1268-77. PubMed ID: 22971544
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor 20 is protective towards dopaminergic neurons in vivo in a paracrine manner.
Boshoff EL; Fletcher EJR; Duty S
Neuropharmacology; 2018 Jul; 137():156-163. PubMed ID: 29698669
[TBL] [Abstract][Full Text] [Related]
8. Protective mechanism of Syringic acid in an experimental model of Parkinson's disease.
Güzelad Ö; Özkan A; Parlak H; Sinen O; Afşar E; Öğüt E; Yıldırım FB; Bülbül M; Ağar A; Aslan M
Metab Brain Dis; 2021 Jun; 36(5):1003-1014. PubMed ID: 33666819
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
10. IGF-1 protects dopamine neurons against oxidative stress: association with changes in phosphokinases.
Ayadi AE; Zigmond MJ; Smith AD
Exp Brain Res; 2016 Jul; 234(7):1863-1873. PubMed ID: 26894890
[TBL] [Abstract][Full Text] [Related]
11. Intranigral ventral mesencephalic grafts and nigrostriatal injections of glial cell line-derived neurotrophic factor restore dopamine release in the striatum of 6-hydroxydopamine-lesioned rats.
Tang FI; Tien LT; Zhou FC; Hoffer BJ; Wang Y
Exp Brain Res; 1998 Apr; 119(3):287-96. PubMed ID: 9551829
[TBL] [Abstract][Full Text] [Related]
12. Expression of magnesium transporter SLC41A1 in the striatum of 6-hydroxydopamine-induced parkinsonian rats.
Lin L; Yan M; Wu B; Lin R; Zheng Z
Brain Res Bull; 2018 Sep; 142():338-343. PubMed ID: 30172737
[TBL] [Abstract][Full Text] [Related]
13. The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages.
Aoi M; Date I; Tomita S; Ohmoto T
Neurosci Res; 2000 Apr; 36(4):319-25. PubMed ID: 10771110
[TBL] [Abstract][Full Text] [Related]
14. Cyclosporin A attenuates the decrease in tyrosine hydroxylase immunoreactivity in nigrostriatal dopaminergic neurons and in striatal dopamine content in rats with intrastriatal injection of 6-hydroxydopamine.
Matsuura K; Makino H; Ogawa N
Exp Neurol; 1997 Aug; 146(2):526-35. PubMed ID: 9270064
[TBL] [Abstract][Full Text] [Related]
15. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
[TBL] [Abstract][Full Text] [Related]
16. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
[TBL] [Abstract][Full Text] [Related]
17. Central neuropeptide-S treatment improves neurofunctions of 6-OHDA-induced Parkinsonian rats.
Bülbül M; Sinen O; Özkan A; Aslan MA; Ağar A
Exp Neurol; 2019 Jul; 317():78-86. PubMed ID: 30825442
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Voluntary Physical Exercise Exerts Neuroprotective Effects and Motor Disturbance Alleviation in a Rat Model of Parkinson's Disease.
Tsai WL; Chen HY; Huang YZ; Chen YH; Kuo CW; Chen KY; Hsieh TH
Behav Neurol; 2019; 2019():4829572. PubMed ID: 31885725
[TBL] [Abstract][Full Text] [Related]
19. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
Vernon AC; Zbarsky V; Datla KP; Croucher MJ; Dexter DT
J Neurochem; 2007 Nov; 103(3):1075-91. PubMed ID: 17714448
[TBL] [Abstract][Full Text] [Related]
20. Impact of Aging on the 6-OHDA-Induced Rat Model of Parkinson's Disease.
Barata-Antunes S; Teixeira FG; Mendes-Pinheiro B; Domingues AV; Vilaça-Faria H; Marote A; Silva D; Sousa RA; Salgado AJ
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32422916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]